Showing Results for: “Contact ”

The American Diabetes Association® applauds the Utah governor and legislature for passing HB 207 Recently, Utah Governor Gary Herbert signed into law American Diabetes Association-supported legislation capping monthly copayments for insulin at $30 for a 30-day supply. House Bill 207 (HB 207) also includes an emergency refill provision that will allow people without an up-to-date prescription to get insulin immediately rather than waiting until they are able to get a refill authorized by a physician, as well as a provision directing the Utah Department of Insurance to issue a report that

Strategic investment backs UpDoc’s clinical AI platform, deploying patient-facing AI agents to transform chronic disease care at scale Today, the American Diabetes Association ® (ADA) announced a strategic investment in UpDoc, an enterprise-ready clinical artificial intelligence (AI) company developing physician-grade agentic AI. The investment from the ADA’s Innovation Fund validates UpDoc’s evidence-based approach to chronic disease management and will accelerate the company’s mission to deliver clinical-grade, agentic AI-powered interventions to millions of people living with diabetes and

Data Shows Potential Breakthrough Treatment Option for Glucose Management in Adolescents with Uncontrolled Diabetes Findings from an international study show a once-weekly injection of dulaglutide was superior in improving glycemic control in youth with type 2 diabetes compared to placebo. The trial was presented at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA) in New Orleans, LA, and simultaneously published in The New England Journal of Medicine. The findings come at a time when cases of type 2 diabetes among youth have more than doubled, since the pandemic

Diabetes Study Adds to Growing Body of Data Around Risk Factors for Long-Standing Effects of COVID-19 Infection A new study reveals that diabetes is a potential risk factor for post-acute sequelae of COVID-19 (PASC), also known as long COVID-19, a range of post-COVID-19 symptoms such as brain fog, skin conditions, depression, and shortness of breath. The findings were presented as a late-breaking poster session at the 82nd Scientific Sessions of the American Diabetes Association® (ADA) in New Orleans, LA. Research shows that up to 10 to 30 percent of individuals that had COVID-19 may

American Diabetes Association Symposium to Highlight Once Weekly Drug as Potential Treatment for Obesity Today, findings from SURMOUNT-1, the first investigational phase 3 trial evaluating the safety and efficacy of tirzepatide for the treatment of obesity, were announced, representing a new class of medicines being studied for the treatment of obesity. The trial was presented at a symposium at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA) in New Orleans, LA, and simultaneously published in The New England Journal of Medicine. Obesity impacts 650 million people

Study shows diabetes patients not taking medication experienced longer hospitalization and recovery with greatest toll among Latinx populations A new study reveals unmanaged diabetes is a key factor in COVID-19 severity and complications, particularly among Hispanic and Latinx populations. Findings of the retrospective study were presented at the virtual 81st Scientific Sessions of the American Diabetes Association ® (ADA). Forty percent of Americans who have died of COVID-19 have had diabetes, and 1 in 10 people with diabetes hospitalized for COVID-19 die within one week – making diabetes a

The American Diabetes Association® (ADA) and Obesity Action Coalition (OAC) today celebrated the progress made in the Texas House of Representatives this session in advancing understanding about the need to address obesity and its impact on the long-term health of the state. House Bill 2677, sponsored by Rep. Senfronia Thompson and co-sponsored by Rep. John Bucy III, would have provided Medicaid coverage for comprehensive treatment for people with obesity. Though HB 2677 cleared the House Public Health Committee with bipartisan support and no registered opposition and was scheduled for a vote

The American Diabetes Association ® applauds the Washington governor and legislature for passing SB 6087 Recently, Washington Governor Jay Inslee signed into law American Diabetes Association (ADA)-supported legislation capping monthly copayments for insulin at $100 for a 30-day supply. Senate Bill 6087 (SB 6087) requires insulin to be covered by state regulated commercial health insurance plans and state employee plans without being subject to a deductible. In addition, any cost sharing the individual is required to pay by their policy will be applied toward their deductible. The bill also